Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · Real-Time Price · USD
36.68
-2.85 (-7.21%)
At close: Jan 23, 2026, 4:00 PM EST
37.40
+0.72 (1.96%)
After-hours: Jan 23, 2026, 7:59 PM EST
Cogent Biosciences Employees
Cogent Biosciences had 205 employees as of December 31, 2024. The number of employees increased by 41 or 25.00% compared to the previous year.
Employees
205
Change (1Y)
41
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,435,961
Market Cap
5.58B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 205 | 41 | 25.00% |
| Dec 31, 2023 | 164 | 26 | 18.84% |
| Dec 31, 2022 | 138 | 61 | 79.22% |
| Sep 30, 2022 | 121 | 44 | 57.14% |
| Dec 31, 2021 | 77 | 62 | 413.33% |
| Dec 31, 2020 | 15 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| PTC Therapeutics | 939 |
| ImmunityBio | 673 |
| Crinetics Pharmaceuticals | 437 |
| CRISPR Therapeutics AG | 393 |
| Immunovant | 362 |
| Mirum Pharmaceuticals | 322 |
| Structure Therapeutics | 218 |
| Kymera Therapeutics | 188 |
COGT News
- 1 day ago - These 20 stocks are strong choices for momentum investors - Market Watch
- 4 days ago - Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR) - GlobeNewsWire
- 10 days ago - Cogent Biosciences, Inc. (COGT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 12 days ago - Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio - GlobeNewsWire
- 18 days ago - Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 21 days ago - Cogent Biosciences Stock Soared in 2025. Four Executives Sold Shares on the Same Day. - Barrons
- 25 days ago - Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis - GlobeNewsWire
- 6 weeks ago - Cogent Biosciences, Inc. (COGT) Discusses Full SUMMIT and Positive APEX Trial Results in Systemic Mastocytosis at ASH Conference Transcript - Seeking Alpha